Bayer’s ATR Inhibitor May Benefit Cancers With ATM Aberrations, Early Data Suggest

September 29, 2020 4:00 pm

Researchers are optimistic that data from a first-in-human clinical trial of Bayer’s ATR-inhibiting agent, BAY-1895344, may pave the way for a new class of precision oncology treatments for patients with certain DNA damage response (DDR) defects in their tumors.

The … Read more

Berzosertib: Protein-Targeting Drug Used to Treat Cancer May Have Same Effect on Coronavirus

June 16, 2020 7:00 pm

Scientists have begun usingĀ berzosertib, a protein-targeting drug, as an accompaniment to chemotherapy for patients with ovarian cancer. The drug is currently in its second phase of trials with cancer patients and is showing promising results for how it … Read more